CLINICAL_TRIALS
trial_result
· 2011-01-13
Clinical Trial Update: Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) [Phase 2]
Summary
Phase 2 trial of alemtuzumab combined with fludarabine in relapsed/refractory B-cell chronic lymphocytic leukemia completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genzyme, a Sanofi Company | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Status: COMPLETED | Results posted: 2011-01-13